We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.15B
AUM Growth
-$403M
Cap. Flow
-$229M
Cap. Flow %
-3.73%
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
64
Reduced
62
Closed
12

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$35.2M
2
SYK icon
Stryker
SYK
+$32.7M
3
UNH icon
UnitedHealth
UNH
+$27.9M
4
PODD icon
Insulet
PODD
+$25.5M
5
RMD icon
ResMed
RMD
+$25.5M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$56.7M
2
ARGX icon
argenx
ARGX
+$45.6M
3
INSM icon
Insmed
INSM
+$43.4M
4
BSX icon
Boston Scientific
BSX
+$42.4M
5
HUM icon
Humana
HUM
+$36.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Industrials 0.05%
3 Communication Services 0.02%
4 Technology 0.02%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRVA icon
76
Privia Health
PRVA
$3.39B
$18.4M 0.3%
1,059,171
– –
HOLX
77
DELISTED
Hologic
HOLX
$18.4M 0.3%
247,826
-42,143
-15% -$3.16M
SRRK icon
78
Scholar Rock
SRRK
$6.33B
$18M 0.29%
2,165,203
– –
SIBN icon
79
SI-BONE Inc
SIBN
$771M
$17.9M 0.29%
1,387,609
+247,653
+22% +$3.54M
APLS
80
DELISTED
Apellis Pharmaceuticals
APLS
$17M 0.28%
444,404
-29,511
-6% -$1.34M
INSP icon
81
Inspire Medical Systems
INSP
$1.46B
$16.7M 0.27%
124,724
-92,970
-43% -$17.6M
NEO icon
82
NeoGenomics
NEO
$1.9B
$16.7M 0.27%
1,202,096
+256,071
+27% +$3.63M
VRNA
83
DELISTED
Verona Pharma
VRNA
$16.4M 0.27%
1,134,229
-5,066
-0.4% -$74K
LEGN icon
84
Legend Biotech
LEGN
$4.31B
$16.4M 0.27%
369,270
+76,000
+26% +$3.51M
FATE icon
85
Fate Therapeutics
FATE
$324M
$15.9M 0.26%
4,839,779
– –
GBIO
86
DELISTED
Generation Bio
GBIO
$11.1M 0.18%
391,886
+5,728
+1% +$186K
HUM icon
87
Humana
HUM
$48B
$10.6M 0.17%
28,440
-107,101
-79% -$36.2M
ASTH icon
88
Astrana Health
ASTH
$2.23B
$10.2M 0.17%
250,617
+240,361
+2,344% +$9.53M
PHR icon
89
Phreesia
PHR
$662M
$9.4M 0.15%
443,341
– –
MRK icon
90
Merck
MRK
$315B
$9.25M 0.15%
74,709
-236,142
-76% -$30.4M
AMGN icon
91
Amgen
AMGN
$198B
$9.23M 0.15%
29,528
+7,389
+33% +$2.17M
ABBV icon
92
AbbVie
ABBV
$450B
$7.24M 0.12%
42,204
+14,611
+53% +$2.42M
GKOS icon
93
Glaukos
GKOS
$9.21B
$6.62M 0.11%
55,926
– –
OMCL icon
94
Omnicell
OMCL
$2.09B
$6.37M 0.1%
235,372
– –
TXG icon
95
10x Genomics
TXG
$5.55B
$6M 0.1%
308,311
– –
ATRC icon
96
AtriCure
ATRC
$1.77B
$4.84M 0.08%
212,559
-234,817
-52% -$5.42M
ILMN icon
97
Illumina
ILMN
$28.2B
$4.55M 0.07%
43,596
-1,221
-3% -$137K
BMRN icon
98
BioMarin Pharmaceuticals
BMRN
$11.5B
$4.3M 0.07%
52,232
-269,555
-84% -$22.4M
ALT icon
99
Altimmune
ALT
$558M
$3.99M 0.06%
+600,000
New +$4.43M
ONC
100
BeOne Medicines Ltd
ONC
$32.4B
$3.66M 0.06%
25,629
+700
+3% +$108K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2024 Portfolio in Review

As of Q2 2024, Bellevue Group held 178 positions worth $6.15B, down 6.1% from $6.56B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $229M in Q2 2024, closing 12 positions and reducing 62 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $34.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Edgewise Therapeutics worth $25.7M.

  • Bellevue Group's largest Q2 2024 buy was Edgewise Therapeutics: 1,428,929 shares worth $25.7M.
  • Bellevue Group added most to Biohaven in Q2 2024, an estimated $35.2M increase.
  • Bellevue Group's biggest Q2 2024 reduction was Intuitive Surgical, cutting an estimated $56.7M.
  • Bellevue Group fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $34.4M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.15B portfolio in Q2 2024.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2024.
  • Bellevue Group's portfolio value fell 6.1% quarter-over-quarter to $6.15B.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.